Platelet hyperaggregability in high-fat fed rats: A role for intraplatelet reactive-oxygen species production

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Monteiro, Priscila F ^a   Morganti, Rafael P ^a   Delbin, Maria A ^b   Calixto, Marina C ^a   Lopes Pires, Maria E ^a   Marcondes, Sisi ^a   Zanesco, Angelina ^b   Antunes, Edson ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

BAY 41 2272; Cyclic GMP; Nitric oxide; Obesity; Platelet aggregation; Reactive oxygen species

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLCYSTEINE; ADENOSINE DIPHOSPHATE; CATALASE; CYCLIC GMP; GUANYLATE CYCLASE; ILOPROST; N ACETYL S NITROSOPENICILLAMINE; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE; THROMBIN; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; CELL RECEPTOR; DIAGNOSTIC AGENT; ENZYME ACTIVATOR; NITRIC OXIDE; NITRIC OXIDE DONOR; SOLUBLE GUANYLYL CYCLASE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; EPIDIDYMIS FAT; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; LIPID DIET; MALE; NONHUMAN; OBESITY; OXIDATIVE STRESS; RAT; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; ANIMAL; BLOOD; BLOOD CLOTTING PARAMETERS; DRUG EFFECT; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; TIME; WEIGHT GAIN; WISTAR RAT;

ADENOSINE DIPHOSPHATE; ANIMALS; ANTIOXIDANTS; BLOOD PLATELETS; CYCLIC GMP; DIET, HIGH-FAT; ENZYME ACTIVATION; ENZYME ACTIVATORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GUANYLATE CYCLASE; INSULIN RESISTANCE; MALE; NITRIC OXIDE; NITRIC OXIDE DONORS; OXIDATIVE STRESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; THROMBIN; TIME FACTORS; WEIGHT GAIN;

EID: 84855786588     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-5     Document Type: Article

References (46)

1. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004, 114:447-53. 10.1016/j.thromres.2004.07.020, 15507277.
2. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol 2007, 27:728-39. 10.1161/01.ATV.0000259359.52265.62, 17272754.
3. Jackson SP. The growing complexity of platelet aggregation. Blood 2007, 109:5087-95. 10.1182/blood-2006-12-027698, 17311994.
4. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008, 28:403-12. 10.1161/ATVBAHA.107.150474, 18174460.
5. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. Br J Haematol 2009, 147:415-30. 10.1111/j.1365-2141.2009.07819.x, 19656155.
6. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear stress. Blood 1996, 88:1525-41.
7. Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008, 6:52-60. 10.2174/157016108783331295, 18220940.
8. Rivera J, Lozano ML, Navarro-Núñez L, Vicente V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009, 94:700-711. 10.3324/haematol.2008.003178, 2675683, 19286885.
9. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001, 103:1718-1720.
10. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54:24-38.
11. De Caterina R, Massaro M, Scoditti E, Annunziata Carluccio M. Pharmacological modulation of vascular inflammation in atherothrombosis. Ann N Y Acad Sci 2010, 1207:23-31. 10.1111/j.1749-6632.2010.05784.x, 20955422.
12. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009, 19:440-449. 10.1016/j.numecd.2009.01.006, 19346117.
13. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PloS Biol 2010, 8:e1000412. 10.1371/journal.pbio.1000412, 2893951, 20613859.
14. Calixto MC, Lintomen L, Schenka A, Saad MJ, Zanesco A, Antunes E. Obesity enhances eosinophilic inflammation in a murine model of allergic asthma. Br J Pharmacol 2010, 159:617-625. 10.1111/j.1476-5381.2009.00560.x, 2828025, 20100278.
15. Possel H, Noack H, Augustin W, Keilhoff G, Wolf G. 2,7-Dihydrodichlorofluorescein diacetate as a fluorescent marker for peroxynitrite formation. FEBS Lett 1997, 416:175-178. 10.1016/S0014-5793(97)01197-6, 9369208.
16. Grillo MA, Colombatto S. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids 2008, 35:29-36. 10.1007/s00726-007-0606-0, 18008028.
17. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605. 10.1161/CIRCULATIONAHA.106.621854, 16894049.
18. Won SJ, Tang XN, Suh SW, Yenari MA, Swanson RA. Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production. Ann Neurol 2011, 70(4):583-590. 10.1002/ana.22538, 22002675.
19. Ku PM, Chen LJ, Liang JR, Cheng KC, Li YX, Cheng JT. Molecular role of GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction of cardiac contractility. Cardiovasc Diabetol 2011, 10:57. 10.1186/1475-2840-10-57, 3141394, 21702924.
20. Thackeray JT, Radziuk J, Harper ME, Suuronen EJ, Ascah KJ, Beanlands RS, Dasilva JN. Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia. Cardiovasc Diabetol 2011, 10:75. 10.1186/1475-2840-10-75, 3170183, 21831292.
21. Yamagishi SI, Edelstein D, Du XL, Brownlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 2001, 50:1491-1494. 10.2337/diabetes.50.6.1491, 11375352.
22. Yngen M, Ostenson CG, Li N, Hjemdahl P, Wallén NH. Acute hyperglycemia increases soluble P-selectin in male patients with mild diabetes mellitus. Blood Coagul Fibrinolysis 2001, 12:109-116. 10.1097/00001721-200103000-00004, 11302472.
23. Yngen M, Ostenson CG, Hjemdahl P, Wallén NH. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med 2006, 23:134-140. 10.1111/j.1464-5491.2005.01765.x, 16433710.
24. Gresele P, Cerletti C, Guglielmini G, Pignatelli P, de Gaetano G, Violi F. Effects of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem 2011, 22:201-211. 10.1016/j.jnutbio.2010.07.004, 21111592.
25. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S, Hirata KI, Kawashima S, Tawa R, Imajoh-Ohmi S, Sakurai H, Yokoyama M. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001, 103:399-409. 10.1016/S0049-3848(01)00341-3, 11553372.
26. Wachowicz B, Olas B, Zbikowska HM, Buczyński A. Generation of reactive oxygen species in blood platelets. Platelets 2002, 13:175-182. 10.1080/09533710022149395, 12180500.
27. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F. gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004, 110:1326-1329. 10.1161/01.CIR.0000134963.77201.55, 15249506.
28. Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B, Walter U. Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway. Blood 2005, 106:2757-2560. 10.1182/blood-2005-03-1047, 15976180.
29. Arthur JF, Gardiner EE, Kenny D, Andrews RK, Berndt MC. Platelet receptor redox regulation. Platelets 2008, 19:1-8. 10.1080/09537100701817224, 18231933.
30. Myhre O, Andersen JM, Aarnes H, Fonnum F. Evaluation of the probes 2',7'-dichlorofluorescin diacetate, luminol, and lucigenin as indicators of reactive species formation. Biochem Pharmacol 2003, 65:1575-1582. 10.1016/S0006-2952(03)00083-2, 12754093.
31. Gibson KR, Neilson IL, Barrett F, Winterburn TJ, Sharma S, MacRury SM, Megson IL. Evaluation of the antioxidant properties of N-acetylcysteine in human platelets: prerequisite for bioconversion to glutathione for antioxidant and antiplatelet activity. J Cardiovasc Pharmacol 2009, 54:319-326. 10.1097/FJC.0b013e3181b6e77b, 19668088.
32. Gibson KR, Winterburn TJ, Barrett F, Sharma S, MacRury SM, Megson IL. Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patientswith type-2 diabetes. Cardiovasc Diabetol 2011, 10:43-51. 10.1186/1475-2840-10-43, 3120650, 21600014.
33. Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, Cavalot F, Trovati M. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998, 21:121-126. 10.2337/diacare.21.1.121, 9538982.
34. Anfossi G, Russo I, Massucco P, Mattiello L, Doronzo G, De Salve A, Trovati M. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest 2004, 34:482-489. 10.1111/j.1365-2362.2004.01370.x, 15255785.
35. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010, 62:525-63. 10.1124/pr.110.002907, 2964902, 20716671.
36. Stasch JP, Hobbs AJN. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009, 191:277-308. 10.1007/978-3-540-68964-5_13, 19089334.
37. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001, 410:212-215. 10.1038/35065611, 11242081.
38. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 2002, 135:333-343. 10.1038/sj.bjp.0704484, 1573147, 11815368.
39. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JPN. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006, 5:755-678. 10.1038/nrd2038, 2225477, 16955067.
40. Roger S, Badier-Commander C, Paysant J, Cordi A, Verbeuren TJ, Félétou M. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide. Br J Pharmacol 2010, 161:1044-1058. 10.1111/j.1476-5381.2010.00943.x, 2998686, 20977455.
41. Gladwin MT. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest 2006, 116:2330-2332. 10.1172/JCI29807, 1555666, 16955136.
42. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arum Kumar HS, Meurer S, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006, 116:2552-2561. 10.1172/JCI28371, 1555649, 16955146.
43. Chirkov YY, Horowitz JD. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?. Pharmacol Ther 2007, 116:287-305. 10.1016/j.pharmthera.2007.06.012, 17765975.
44. Hoffmann LS, Schmidt PM, Keim Y, Schaefer S, Schmidt HH, Stasch JP. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol 2009, 157:781-795. 10.1111/j.1476-5381.2009.00263.x, 2721263, 19466990.
45. Schäfer A, Flierl U, Kobsar A, Eigenthaler M, Ertl G, Bauersachs J. Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats. Arterioscler Thromb Vasc Biol 2006, 26:2813-2818. 10.1161/01.ATV.0000249407.92147.12, 17023677.
46. Noé L, Peeters K, Izzi B, Van Geet C, Freson K. Regulators of platelet cAMP levels: clinical and therapeutic implications. Curr Med Chem 2010, 17:2897-2905. 10.2174/092986710792065018, 20858171.